Changing the Game - Aiming to Cure.

Muhi is Tr1X's Senior Director of Clinical Operations and is responsible for bringing Tr1X's products to the clinic. Over the past decade in industry, she has managed and led over 25 studies ranging from Phase I, first in human (FiH) to global Phase III trials. Muhi is experienced in a variety of therapeutic areas including Immuno-Oncology, CNS and Ophthalmology. Prior to joining Tr1X, she was Asset Lead at Janux Therapeutics where she helped the company transition from R&D to a clinical stage company. Prior to that she held positions of increasing responsibility at Mirati, Fate Therapeutics and global CROs. Muhi holds a BS in Biology from CSU Pomona.

Lyndsey serves as Tr1X’s Senior Director of Quality. Lyndsey has over 15 years of experience in quality and product development across multiple modalities, including cell therapy products, biologics, small molecules, and devices. Lyndsey's focus is on establishing quality organizations and leading GXP oversight for commercial and clinical phase programs. Prior to joining Tr1X, she worked for large and small companies including Nohla Therapeutics, Amgen, and Halozyme Therapeutics. Lyndsey is a Certified Quality Auditor and Certified Manager of Quality/Organizational Excellence and holds a BS in Chemistry from the University of Michigan.

Jonathan Perrin serves as Tr1X's General Counsel and Senior Director of Operations. Prior to joining Tr1X, he was a partner at Massumi & Consoli LLP, a boutique law firm specializing in private equity M&A. Prior to MCLLP, he was a member of the Technology Companies & Life Sciences group at Goodwin Procter. Jon has represented venture-backed clients on a variety of matters, including complex domestic and cross-border transactions, financings and general corporate matters. He has a Bachelor of Arts from Harvard College and a JD from UCLA.

Xavier oversees Tr1X's Clinical Development team and is responsible for executing on the Company's clinical programs. Prior to Tr1X, Xavier served as head of clinical development across a series of biotechnology companies including Design Therapeutics, Strongbridge Biopharma and Boston Pharmaceuticals, where he was responsible for all aspects of clinical development from IND submission through BLA filings. Prior to his career in biotechnology, Xavier served in positions of increasing responsibility in immunological clinical development at BMS and Novo Nordisk. Xavier also spent six years at NIH researching the role of regulatory T cells in tolerance. Xavier holds an MD from the School of Medicine at the National University of Mexico and is a board certified rheumatologist.

Fuad is an Associate Scientist at Tr1x in the Process Development team. He graduated from California State University, Northridge with a BS in Biology. He brings over 11 years of experience in biotechnology and gene therapy working for companies like Biolegend, Kite Pharma, Poseida therapeutics in process optimization and most recently at Fate Therapeutics where he was helping develop and characterize newly generated iPSC cell lines and across the manufacturing function for a variety of potential new therapies. His passion continues to drive his work and contribute to the field of biotechnology to improve patient outcomes.

Robert is a Scientist II in Tr1x's Biology team. Prior to joining Tr1x, he studied regulatory T cell biology as a postdoctoral researcher in the laboratory of Maria Grazia Roncarolo at Stanford University. Robert received his BS in Biochemistry from California Polytechnic State University and his PhD in Pharmacology and Toxicology with a dual major in Environmental Toxicology from Michigan State University.

Steven is a Senior Research Associate on the Biology team at Tr1x. Prior to Tr1x, Steven has spent the last 4 years in the biotech industry working primarily in the gene editing and immuno-oncology arenas at Editas Medicine, Artisan Biotechnologies, and most recently at Fate Therapeutics as a part of the iPSC T Cell therapy team. Steven graduated from Emmanuel College in Boston, MA with a degree in Biochemistry. When not in lab he can be found getting up to anything and everything outdoors thanks to his New Hampshire upbringing.

Jan de Vries has more than 30 years of experience in drug discovery and development. Prior to serving as Tr1X's co-founder and inaugural CEO, he was the CEO of AIMM Therapeutics, a therapeutic antibody company which discovered Beyfortus® and licensed it to Medimmune/AstraZeneca. Prior to that Jan was a SVP at Novartis and global head of the Disease Area, Autoimmune-Inflammatory Diseases and Transplantation, where he led the discovery and early development of (amongst others): Elidel®, Cosentyx®, Gilenya®, Ilaris® and Maizent®. Jan holds a PhD in Immunology from the University of Amsterdam and did his postdoctoral studies in the field of tumor immunology with Dr John Mendelsohn at the University of California, San Diego.

Maria Grazia is the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, founder of the Center for Definitive and Curative Medicine, and former co-director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. Dr. Roncarolo has spent her career translating discoveries in immune-mediated diseases and regenerative medicine into novel patient therapies. Dr. Roncarolo and her team were the first to discover T regulatory Type 1 cells in patients, and the first to develop curative treatments for ADA-SCID. A pediatric immunologist by training, she was instrumental in bringing novel cell and gene therapies to market including Strimvelis® and Libmeldy®. Dr Roncarolo is a co-founder of the gene-editing company Graphite Bio (NSDQ: GRPH), where she still serves as the Chair of the Scientific Advisory Board.

Xavier is an immunologist and translational scientist with over 25 years of experience in Research & Development across an array of therapeutic areas including immune-inflammation, (immuno)-oncology and precision medicine. Prior to joining Tr1X, Xavier served as the Vice President Immunology at Personalis where he led the development of precision cancer therapies, and the integration of genomic, immunological and clinical data to enable precision oncology. Prior to that, he held positions of increasing responsibility in pharmaceutical and biotechnology companies including Ultragenyx, MedImmune, ARYx, Gryphon, Merck, and Chiron. Xavier has contributed to multiple successful global drug approvals including Proleukin®, Gardasil®, FluMist® quadrivalent, and Imfinzi®). He holds a PhD in Immunology and a PharmD from the Claude Bernard University in Lyon.

David has over a decade of experience founding and scaling companies at the intersection of healthcare and technology. Prior to Tr1X, David was Co-Founder and COO of Arine, a therapeutic optimization company he helped launch and scale to serve millions of patients across the US. Before that, he worked at Proteus Digital Health, one of the first techbio companies and the first in the field to obtain FDA approval for a digital medicine, Abilify MyCite®. Previously, David worked on various initiatives related to innovative healthcare payment models and the impact of the Affordable Care Act. David holds an undergraduate degree from Harvard and completed his graduate studies at the University of Cambridge.

James has 30 years of operational experience across a wide range of disciplines including research and development, manufacturing, quality operations, and marketing and sales. He most recently served as Vice President of Manufacturing at Sonoma Biotherapeutics where he created a technical operations team in support of developing cell therapies targeting autoimmune disorders. Prior to joining Sonoma, James led the clinical manufacturing division at the Fred Hutch Cancer Research Center where he had direct responsibility for the technical components of over 20 INDs and 9 DMFs involving both biologics and cell & gene therapy products. James has a Master’s in Business Administration from Rivier University and a BS in Microbiology from Michigan State University.

Daryl is a Senior Principal Scientist in Vector Engineering at Tr1X. He has done extensive molecular virology research in the HIV field, and previously served as a Senior Scientist at Sana Biotechnology identifying cellular factors restricting gene therapy. Daryl received a PhD in Molecular and Cellular Biology from the University of Washington.

Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the National Academy of Medicine. Dr. Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Dr. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology.

Dr. Luigi Naldini, is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He has received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy). For the past 25 years he has pioneered the development and the applications of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also allowed novel insights into hematopoietic stem cell function, induction of immunological tolerance, and tumor angiogenesis. His work also contributed to advance the use of artificial nucleases for targeted genome editing in cell and gene therapy. He has published over 280 scientific papers.

Jie serves as Tr1X’s Director of Analytical Sciences. Jie has developed expertise on analytical development via working through different therapeutic fields, including siRNA therapeutics, monoclonal antibody therapies targeting cancer stem cells and immune check points, and cell therapies, most recently as a principal scientist as the head of analytical development at Cero Therapeutics. Jie holds a PhD in Biochemistry and Plant Physiology from the Chinese Academy of Sciences.

Vikas works as a Senior Scientist in Tr1X's Bioanalytical Development team. Previously Vikas worked with bispecific biologics targeting cancer neoantigens, studied regulatory T cell migration and stability and the role of microbiota in solid organ transplantation. He has experience working with in vivo mouse and non-human primate models. Vikas received his PhD in virology from Academia Sinica, Taipei, Taiwan and Bachelor's in veterinary medicine (DVM) from Pantnagar, India.

Molly is a Senior Scientist in Tr1x’s Biology team. Before joining Tr1x, Molly worked on assay development on regulatory T cells, gene editing, and cell line development. Molly received her PhD from Stanford’s Stem Cell Biology and Regenerative Medicine in the lab of Maria Grazia Roncarolo and her B.S. in Molecular, Cellular, Developmental Biology from UCLA.

Audrey is a Sr. Research Associate on the Biology team. Prior to working at Tr1X, Audrey worked in the biotech industry for 4 years across cancer drug development and early adenovirus research. She recieved her Bachelor's degree in Biology and Psychology from US Santa Cruz.

Kevin is a Process Engineer II in Tr1X’s Process Development team. He brings over 7 years of experience spanning roles in research to technical operations across multiple drug modalities. Recently, Kevin’s work has focused on the optimization of production and manufacturing processes for therapeutic applications. Kevin is currently pursuing a master’s degree at San Diego State University and received his undergraduate degree from California State University, East Bay.

Michelle is a Research Associate in Tr1X's Vector Engineering department. Michelle brings her experience in cell culturing primary cells to Tr1X from her previous position at Crown Bioscience. She also helped with bat cochlea research during her time in undergrad at UC Merced where she graduated with a B.S. in Evolutionary and Ecological Biology.

Alex is a Research Associate II in Tr1X's Bioanalytical Developmental team. Alex has worked at the Genomics Institute of the Novartis Research Foundation in the Cancer Therapeutics Department and her most recent role was at Becton Dickinson working in the Hybridoma/Antibody Development group. She graduated from San Diego State University in 2020 with a degree in Cell and Molecular Biology and completed a CIRM fellowship and IMSD internship during her time at SDSU.

Matt serves as Tr1X's Director of Process Development. Matt has over a decade of dedicated experience in cell and gene therapy process development and manufacturing. Before joining Tr1X, Matt was the Associate Director of Manufacturing Sciences and Technology at Poseida Therapeutics where he was overseeing multiple functions within Tech Ops, including classical MSAT, late stage process development, and manufacturing data science & engineering. Matt holds a MS in Biotechnology from Johns Hopkins University and an MBA from the University of Illinois.